PACB — PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Nasdaq · Unknown · Unknown · CIK 1299130 ·
Last close
$1.34
Market Cap
$416.21M
52W High
$1.80
52W Low
$1.09
ADV30
6,173,047
Next earnings
2026-08-06
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 37,178,000 12,841,000 -54,153,000 -8,275,000 782,365,000 56,274,000 779,999,000
Dec 2025 44,645,000 16,566,000 -41,197,000 -40,371,000 784,083,000 63,707,000 778,734,000
Sep 2025 38,441,000 15,901,000 -38,877,000 -38,000,000 803,158,000 56,467,000 767,068,000
Jun 2025 39,766,000 14,684,000 -44,853,000 -41,930,000 825,470,000 54,803,000 763,981,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-111,209,000
Investing CF
$115,448,000
Financing CF
$3,428,000
CapEx
$-9,417,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.84
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,695,302,000
Inventory
$49,285,000
Receivables
$35,448,000
ST Investments
$215,799,000
EBIT TTM
$-539,104,000
Pretax Income TTM
$-546,058,000
Interest Exp TTM
$6,954,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$160,030,000
EBITDA
$-143,146,000
Free Cash Flow
$-48,237,124
Enterprise Value
$849,738,304
Total Cash
$275,961,984
Total Debt
$706,387,968
Shares Out
310,601,688
Trailing EPS
$-0.41
Book Value
$0.01
ROE
-273.6%
ROA
-12.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 160,005,000 -557,561,000 -546,376,000 784,083,000 778,734,000 -111,209,000
Dec 2024 154,014,000 -290,663,000 -309,851,000 1,260,447,000 753,853,000 -206,058,000
Dec 2023 200,521,000 -310,365,000 -306,735,000 1,746,013,000 1,044,709,000 -259,173,000
Dec 2022 128,304,000 -304,819,000 -314,248,000 1,767,086,000 1,204,182,000 -263,211,000

TTM Snapshot

Revenues TTM
$162,856,000
NetIncome TTM
$-188,023,000
OpCashFlow TTM
$0
Assets (Latest)
$1,260,447,000
Forward EPS
$-0.40

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.50 · spot: $1.34 · call volume: 79 · put volume: 91
Expected Move to 2027-01-15: ±$0.87 (64.93%) — implied range $0.47$2.21 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CCAP Crescent Capital BDC, Inc. $415.99M $11.29
DFP Flaherty & Crumrine Dynamic Preferred & Income Fund Inc $418.57M $20.38
MVST Microvast Holdings, Inc. $419.78M $1.26
JOUT JOHNSON OUTDOORS INC $421.72M $45.50
VRNO Verano Holdings Corp. $422.81M $5.72

News headlines (Yahoo Finance, 1h cache)

Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street?
2026-06-16 12:53 · Yahoo
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
2026-06-15 18:48 · Yahoo
3 Unprofitable Stocks That Concern Us
2026-06-15 13:00 · Yahoo
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
2026-06-12 22:15 · Yahoo
Global Next Generation Sequencing Services Market Size/Share Worth USD 56.1 Billion by 2035 at a 23.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation,
2026-06-11 10:30 · Yahoo
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets
2026-06-07 05:11 · Yahoo
Here's Why You Should Add PacBio Stock to Your Portfolio Now
2026-06-03 17:43 · Yahoo
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
2026-06-02 18:21 · Yahoo
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
2026-06-02 16:09 · Yahoo
3 Russell 2000 Stocks Walking a Fine Line
2026-05-29 20:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.